|
KMID : 1001020090070030125
|
|
Journal of Urologic Oncology
2009 Volume.7 No. 3 p.125 ~ p.130
|
|
|
Current Concepts in Androgen Deprivation Therapy for Prostate Cancer: New Approaches to Target Androgen Receptor
|
|
Kwak Cheol
|
|
|
Abstract
|
|
|
|
Prostate specific antigen (PSA) is still prognostic factor in hormone-refractory prostate cancer (HRPC), and it means activated androgen receptor (AR) is needed even in this situation. Actually many evidences which show AR plays an important role for proliferation in HRPC and HRPC is under the control of androgen lead a new horizon of view. Recently, we have noticed that HRPC can produce endogenous androgen by classic and backdoor pathway and maintain high intracellular dihydrotestosterone (DHT) level. Thus, ketoconazole has been refocused, and new drugs which can block androgenic steroid synthetic pathway such as abiraterone acetate are becoming newly prominent. Other drugs to target AR is still under investigation and they showed promising initial results. Even argue that ‘hormone-refractory’ is misnomer has been raised.
|
|
|
KEYWORD
|
|
|
Androgen deprivation therapy, Prostate cancer, Androgen receptor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|